Liraglutide vs Mazdutide.

Liraglutide is a long-acting, injectable glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated analog of the human incretin hormone GLP-1. It is roughly 97% homologous to native GLP-1, differing by an arginine-for-lysine substitution at position 34 and a C16 palmitic-acid chain attached via a glutamic-acid spacer at lysine 26. That fatty-acid acylation promotes reversible binding to serum albumin and self-association, slowing degradation and renal clearance enough to extend its action to once-daily dosing. It is marketed by Novo Nordisk as Victoza (type 2 diabetes) and Saxenda (chronic weight management), and is now also available as an FDA-approved generic.

Mazdutide (IBI362, originally LY3305677) is an investigational once-weekly injectable dual agonist of the GLP-1 and glucagon receptors, based on a mammalian oxyntomodulin analog. It is being developed by Innovent Biologics under a license from Eli Lilly, primarily for obesity and type 2 diabetes and with additional metabolic indications under study. It is furthest advanced in China, where it has progressed through Phase 3 trials, but it is not an approved medicine in the United States or Europe. Like other dual agonists, it is designed to pair appetite and glucose control with added energy expenditure.

Liraglutide binds and activates the GLP-1 receptor, a Gs-protein-coupled receptor that raises intracellular cyclic AMP. In pancreatic beta cells this potentiates glucose-dependent insulin secretion, meaning insulin release is amplified mainly when blood glucose is elevated; it also suppresses inappropriately high glucagon secretion from alpha cells, which together improve postprandial and fasting glucose. Because the effect is glucose-dependent, GLP-1 agonism carries low intrinsic hypoglycemia risk as monotherapy. Liraglutide additionally slows gastric emptying and acts on hypothalamic appetite circuits to increase satiety and reduce food intake, the basis for its weight-lowering effect.

Mazdutide derives from oxyntomodulin, a natural gut hormone that engages both the GLP-1 and glucagon receptors. GLP-1 activation drives appetite suppression, delayed gastric emptying, and glucose-dependent insulin release, while glucagon-receptor activation is thought to increase energy expenditure and reduce hepatic fat. The combined signaling is intended to produce weight loss alongside improvements in lipids, blood pressure, liver enzymes and other metabolic markers. Structural modifications extend its half-life to allow weekly subcutaneous administration.

Human evidence for liraglutide is extensive and high-quality, not preclinical extrapolation. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; n=9,340 with type 2 diabetes at high cardiovascular risk, median 3.8-year follow-up) found a lower rate of the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke versus placebo, plus lower cardiovascular and all-cause mortality; its design was prespecified (Marso et al., Am Heart J 2013). For obesity, the 56-week SCALE trial in adults without diabetes (Pi-Sunyer et al., NEJM 2015; n=3,731) showed significantly greater weight loss with liraglutide 3.0 mg plus lifestyle than with placebo plus lifestyle. Liraglutide has also been studied in adolescents with obesity and in prediabetes. The main human gaps now are comparative: newer agents such as semaglutide and tirzepatide produce larger weight reductions in head-to-head and cross-trial comparisons, and liraglutide's once-daily injection is a practical disadvantage.

A randomised, double-blind, placebo-controlled Phase 2 trial in 248 Chinese adults with overweight or obesity, published in Nature Communications (2023), tested mazdutide 3 mg, 4.5 mg and 6 mg over 24 weeks. Mean body-weight reductions reached roughly 11% at the 6 mg dose versus about 3% with placebo, with dose-dependent effects. Participants also showed improvements in waist circumference, blood pressure, blood lipids, liver transaminases and serum uric acid. Earlier Phase 1b studies in Chinese adults with overweight/obesity and with type 2 diabetes supported tolerability and metabolic benefit at higher doses. Phase 3 obesity and diabetes programs (the GLORY series) have since been conducted in China, and GLORY-1, a randomised placebo-controlled Phase 3 trial of once-weekly mazdutide in Chinese adults with obesity or overweight, was published in the New England Journal of Medicine in 2025. A further Phase 2 randomised controlled trial in Chinese adults with a body mass index of at least 30 and without diabetes was reported in Med, and mazdutide has been included in network meta-analyses of glucagon receptor agonists that pool metabolic outcomes across compounds. Evidence outside Chinese populations and long-term outcome data remain limited. The trials are sponsor-run, of moderate size, and almost entirely single-country, so generalisability to other ancestries, body-composition distributions and background diets is untested. There is no cardiovascular outcome trial for mazdutide, no published head-to-head randomised comparison with semaglutide or tirzepatide, and no multi-year durability or weight-regain dataset. By contrast, semaglutide and tirzepatide each have global multi-thousand-participant Phase 3 programs and regulatory approval in the United States and Europe, and semaglutide additionally has dedicated cardiovascular outcome data, which places mazdutide an evidence tier behind them despite broadly similar reported weight reductions. Regulatory acceptance in one country also does not substitute for the outcome evidence that has not yet been generated.

The most common documented adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually dose-related and most pronounced early in treatment. Labeled warnings include acute pancreatitis, acute gallbladder disease (cholelithiasis/cholecystitis), acute kidney injury (often in the setting of dehydration from GI losses), and increased heart rate; in glucose-lowering combinations with insulin or sulfonylureas, hypoglycemia risk rises. Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent medullary thyroid carcinoma findings, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2; whether this risk translates to humans remains unresolved. Long-term safety in non-medical, non-prescribed "research" use is uncharacterized, and unregulated/compounded sources add contamination and mislabeling risks.

Across trials, the most common adverse events were gastrointestinal, including nausea, diarrhoea and decreased appetite, typical of GLP-1-based agents and generally most pronounced during dose escalation. Overall tolerability was described as favorable in the Phase 2 study, but as an investigational drug its full safety profile, including uncommon and long-term risks, is not yet established. Glucagon-receptor activation warrants monitoring of parameters such as heart rate and hepatic markers in ongoing studies. Documented class considerations for incretin-based agents include gallbladder and biliary events, reported pancreatitis, delayed gastric emptying with implications for sedation and anaesthesia, loss of lean mass in parallel with fat loss, and rodent thyroid C-cell findings that shaped labelling for several approved GLP-1 drugs. A trial adequate to characterise these requires scheduled laboratory chemistry, vital-sign monitoring, pregnancy prevention requirements, protocol-defined dose-reduction and stopping rules, and independent adjudication of serious events, none of which exists outside a regulated study. Mazdutide is not approved or commercially supplied in the United States or Europe, so material sold there as mazdutide comes from unregulated research-chemical or compounding channels with no verified identity, potency, purity or sterility, no stability data, and no route for reporting harm. Peptide products from such channels have been associated with mislabelling and contamination, which makes any observed effect, benign or adverse, difficult to attribute to the intended molecule.

FDA-approved: as Victoza (2010) for type 2 diabetes in adults and later adolescents, and as Saxenda (2014) for chronic weight management; a generic liraglutide injection has since been approved. It is a legitimately prescribed medication, not a research-only compound, and is not a banned substance under standard anti-doping frameworks the way some hormones are.

Mazdutide is investigational and not approved by the FDA or EMA. Its development is most advanced in China, where a regulatory filing for obesity/overweight has been pursued following Phase 3 results. Any use outside an authorized clinical trial is unapproved.